We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01548222
Recruitment Status : Completed
First Posted : March 8, 2012
Last Update Posted : August 27, 2013
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a trial to determine if patients who are well controlled and on basal insulin are treated with excessive basal dose.

Condition or disease
Type 2 Diabetes

Detailed Description:
In many clinical trials, basal insulin is titrated to only a fasting glucose goal. The usual final dose is >0.4U/kg. In carefully CGM monitored/titrated studies in both basal insulin alone or in pump-treated T2DM, we have found the basal insulin dose to be <0.3U/kg. This suggests that if guided by a single daily fasting glucose, titration may result in an excessive basal dose. This study will examine that issue.

Study Design

Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target
Study Start Date : February 2012
Primary Completion Date : December 2012
Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Insulin
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. Percentage of time CGM glucose is <70mg/dl [ Time Frame: the subject will be followed for 9 days ]
    The percentage of time CGM glucose is <70 mg/dl during the basal glucose evaluation


Secondary Outcome Measures :
  1. Percentage of time CGM glucose is <40 mg/dl [ Time Frame: the subject will be followed for 9 days ]
    The percentage of time the CGM glucose is <40 mg/dl

  2. Determined hypoglycaemic episodes [ Time Frame: the subject will be followed for 9 days ]
    The percentage of subjects who perceived all CGM determined hypoglycaemic episodes

  3. Weight gain [ Time Frame: the subject will be followed for 9 days ]
    The mean weight gain since initiating basal insulin fromo retrospectively gathered data.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects will be recruited from the Diabetes Care Center clinic
Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • Age 18 years and above
  • Concurrently on +/-thiazolidnedione +/-DDP IV inhibitors +/-metformin +/- glinides and basal insulin analogs
  • A1C 10% or below
  • Capable of self monitoring glucose at least 4 x a day
  • Previously compliant with clinical recommendations
  • Fasting blood glucose <110mg/dl average for 3 consecutive days
  • BMI <45 kg/m

Exclusion Criteria:

  • Urinary ketosis
  • Current or expected alternation in insulin sensitivity such as major surgery, infection, renal failure, glucocorticoid treatment, recent serious hypoglycaemic episode
  • Currently participating in another clinical trial
  • Using rapid insulin insulin
  • Pregnancy or nursing or the intention of becoming pregnant or not using adequate birth control
  • Significant liver or heart failure.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01548222


Locations
United States, California
Diabetes Care Center
Salinas, California, United States, 93901
Sponsors and Collaborators
Diabetes Care Center
Medtronic
More Information

Publications:
Responsible Party: Diabetes Care Center
ClinicalTrials.gov Identifier: NCT01548222     History of Changes
Other Study ID Numbers: MM2012
First Posted: March 8, 2012    Key Record Dates
Last Update Posted: August 27, 2013
Last Verified: August 2013

Keywords provided by Diabetes Care Center:
type 2 diabetes
continuous glucose
basal insulin

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs